Gemtuzumab(Mylotarg) is an innovative drug designed for CD33-positive acute myeloid leukemia, which has brought new hope for treatment to many patients. However, like other drugs, Gemtuzumab is not without side effects. During use, patients may encounter a series of adverse reactions, which require our close attention and attention.

Adverse reactions of Gemtuzumab(Mylotarg)

As a drug for the treatment of CD33-positive acute myeloid leukemia, Gemtuzumab(Mylotarg) has brought hope to patients, but it may also cause a series of adverse reactions during use. The following is a detailed description of these adverse reactions:

1. Bleeding tendency

During Gemtuzumab treatment, patients may have a decrease in platelet count due to the effect of the drug on the hematopoietic system, thereby increasing the risk of bleeding. This may cause patients to experience varying degrees of bleeding symptoms such as nosebleeds, cerebral hemorrhages, skin ecchymoses, and hematuria. Therefore, patients should pay close attention to any abnormal bleeding during treatment and inform their doctors in a timely manner.

2. Reduced immunity

Gemtuzumab may reduce the patient's immunity and increase the risk of infection. Patients may experience symptoms of infection such as fever, chills, and cough. During treatment, patients should pay special attention to personal hygiene, avoid contact with sick people, and report any signs of infection to their doctors in a timely manner.

3. Fever reaction

Fever is one of the common side effects of Gemtuzumab. This may be due to an immune response or infection caused by the drug. When a patient has a fever, he should measure his body temperature in time and consult a doctor whether he needs to take antipyretic drugs. Maintaining adequate water intake helps maintain a stable body temperature.

4. Gastrointestinal discomfort

Nausea and vomiting are also common adverse reactions to Gemtuzumab. This may be due to the irritation of the drug to the gastrointestinal tract. Patients can try to adjust the time of medication to relieve gastrointestinal discomfort. Keeping a light diet and avoiding greasy food can also help relieve nausea and vomiting symptoms.

5. Constipation problem

Gemtuzumab may cause slower intestinal peristalsis, which in turn causes constipation. Patients can relieve constipation symptoms by increasing dietary fiber intake, drinking more water, and exercising appropriately. If symptoms continue to worsen, consult a doctor in time.

6. Headache phenomenon

Some patients may experience headache symptoms after using Gemtuzumab. This may be due to the effect of the drug on the nervous system. Patients should get enough rest when they have a headache and avoid overwork. If the headache persists or worsens, you should seek medical attention in time.

7. Abnormal liver function

Gemtuzumab may cause an increase in liver function-related indicators such as AST and ALT, which usually means that the liver may be damaged to a certain extent. Patients should undergo regular liver function tests during treatment. If AST and ALT are found to be elevated, they should be reported to the doctor in time so that the treatment plan can be adjusted or other necessary measures can be taken.

These adverse reactions do not occur in every patient, and their severity varies from person to person. During Gemtuzumab treatment, patients should pay close attention to their physical condition and report any discomfort or abnormal symptoms to the doctor in time. The doctor will adjust the treatment plan or take other necessary measures according to the patient's specific situation to ensure the safety of treatment.

As a highly effective therapeutic drug, Gemtuzumab can bring significant therapeutic effects to patients, but it is also accompanied by a certain risk of adverse reactions. To ensure that the treatment is effective, both patients and doctors need to be vigilant about these adverse reactions and take necessary preventive and countermeasure measures. Only in this way can we maximize the therapeutic potential of gemtuzumab ozogamicin and bring patients better survival chances and quality of life.